# OnCo record renal-cell-carcinoma-signalling (pathway). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/pathways/renal-cell-carcinoma-signalling/>
  a schema:BioChemEntity ;
  onco:kind "pathway" ;
  schema:identifier "renal-cell-carcinoma-signalling" ;
  schema:name "Renal cell carcinoma (KEGG map)"@en ;
  schema:alternateName "KEGG hsa05211"@en, "Renal cell carcinoma"@en ;
  schema:description "KEGG's kidney cancer map shows how losing VHL lets the oxygen sensor HIF pile up and order new blood vessels (VEGF, PDGF), while MET and PI3K drive growth in other subtypes. Anti-VEGF drugs, HIF-2a inhibitors and immunotherapy all act on this circuit."@en ;
  schema:url <https://onco.cc/pathways/renal-cell-carcinoma-signalling/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.kegg.jp/pathway/hsa05211>, <https://doi.org/10.1038/nrdp.2017.9> ;
  onco:related <https://onco.cc/pathways/hif-vhl/>, <https://onco.cc/pathways/vegf-angiogenesis/> ;
  onco:cancers <https://onco.cc/cancers/rcc/> ;
  onco:targets <https://onco.cc/targets/hif2a/>, <https://onco.cc/targets/vegf/>, <https://onco.cc/targets/met/>, <https://onco.cc/targets/kras/>, <https://onco.cc/targets/mtor/> ;
  onco:drugs <https://onco.cc/drugs/belzutifan/>, <https://onco.cc/drugs/sunitinib/>, <https://onco.cc/drugs/pazopanib/>, <https://onco.cc/drugs/axitinib/>, <https://onco.cc/drugs/cabozantinib/>, <https://onco.cc/drugs/lenvatinib/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/drugs/everolimus/>, <https://onco.cc/drugs/temsirolimus/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/savolitinib/> ;
  onco:pathways <https://onco.cc/pathways/hif-vhl/>, <https://onco.cc/pathways/vegf-angiogenesis/>, <https://onco.cc/pathways/pi3k-akt-mtor/>, <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/rtk-activation/>, <https://onco.cc/pathways/pd1-checkpoint/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-hsieh-nat-rev-dis-primers/> .